Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use NEXOBRID safely and effectively. See full prescribing information for NEXOBRID. NEXOBRID® (anacaulase-bcdb), for topical gelInitial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
NEXOBRID is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. Limitations of Use The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns Burns on the face, perineum, or genitalia Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease Circumferential burns Burns in patients with significant cardiopulmonary disease, including inhalation injury NEXOBRID is not recommended for: Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance. Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal.
- generic_name
- anacaulase-bcdb
- brand_name
- STERILE
- product_names
- ANACAULASE-BCDB, STERILE
- ndc
- 69866-2002, 69866-2002-3, 69866-2000, 69866-2000-1, 69866-2001, 69866-2001-2, 69866-2005, 69866-2005-3, 69866-2003, 69866-2003-1, 69866-2004, 69866-2004-2, 69866-2015, 69866-2015-3, 69866-2013, 69866-2013-1, 69866-2014, 69866-2014-2
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en